LONDON, UK (GlobalData), 18 February 2016 - Although excitement surrounding recent trials of T-cell therapies and their ability to treat blood cancer has been widespread of late, there are lingering questions about their marketability, says an analyst with research and consulting firm GlobalData.

To date, T-cell therapy trials have produced exciting results, meaning such treatments have been hailed as the next big advancement in personalized immunotherapy. For example, after one such trial, researchers at a cancer research institution in Washington reported that six out of seven patients experienced complete remission.

However, Cai Xuan, Ph.D., GlobalData's Analyst covering Oncology and Hematology, states that: "The cost of T-cell therapy is currently estimated at a staggering $300,000 per patient, with some estimates pegging the cost at over $500,000. Given this, T-cell therapies must show curative ability in order to justify such a high price tag in comparison to existing treatment options such as stem cell transplantation, which can cost from around $100,000 to $200,000.

"In order to do this, more trials must be conducted. To date, only a handful have gone ahead, in a limited number of patients, due to the high cost, as well as the long and difficult manufacturing processes involved in administering T-cell therapy. This presents a huge scalability problem which cannot easily be solved."

While cost and scalability are both significant issues, perhaps the most difficult barrier T-cell therapy will have to overcome is its poor safety profile. Even in the limited data released so far, fatal cases of tumor lysis syndrome, cytokine release syndrome, and other organ-specific toxicities have been reported.

Xuan continues: "The aggressive nature of T-cell therapy's side effects means it is highly unlikely to replace current frontline therapy options. On top of this, the lack of long-term follow-up data presents the danger of additional long-term toxicities being revealed in the future.

"Data suggesting impressive remission rates of up to 90% in treated patients are preliminary, and it is still too early to tell if these remissions will turn into cures. T-cell therapy is undoubtedly a significant step forward for immunotherapy, but whether it will reach the status of a breakthrough cure remains to be seen."

-ENDS-

-NOTES TO EDITORS-

- Comments provided by Cai Xuan, Ph.D., GlobalData's Analyst covering Oncology and Hematology.

For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx

-ABOUT GLOBALDATA-

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)161 359 5822 or at pr@globaldata.com.

More HCB News